TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in baseline heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in baseline Stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in baseline headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Solicited Local Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever)
Endpoint domain: Adverse events/effects
Primary endpoint: Antenatal detection rate of clubfeet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Pulmonary Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in Upper Extremity Fugl Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Polyp Number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of patients with thyroid function parameters within the intended level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post Surgical Drain Output in CCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daytime QT interval corrected for heart rate (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in baseline fasting blood lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in baseline lipoprotein (a), lipoprotein particle number and size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in baseline low density lipoprotein (LDL) peak size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowering of IOP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Systemic Lupus Activity Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PHQ-9 (The Patient Health Questionnaire-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS Pain (Visual Analog Scale for Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3-5 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of therapeutic products generated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of consultations per healthcare provider
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of indomethacin doses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days to a regular diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Oxidative Stress markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxygen saturation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportional Change in D-dimer Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of cancer recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Developed Acute Rejection Episode
Endpoint domain: Adverse events/effects
Primary endpoint: acute GvHD incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virological Response 24 Weeks After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation rate of patients with prior warfarin use
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of major bleeding events of patients with prior warfarin use
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of hospitalization due to major bleeding events of patients with warfarin use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: number of T2 gadolinium enhancing lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: expanded disease severity score (EDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of biopsy proven acute rejection
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Clinical Response at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with ocular adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Successful First Attempt at Endotracheal Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Arterial Oxygen Saturation Nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Flash visual evoked potentials (FVEP) at 4 weeks of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bayley Scales of Infant Development, Second Edition (BSID-III) at 18 months of age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Composite adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: progressive-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Size of anterior femoral notch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kujala Score changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KOOS questionnaire changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radionuclide tracer uptake at the surgically created notch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of peri-implantitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of correct femoral tunnel position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood flow velocity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Central Nervous System Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Response rate (RR) after six cycles of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission rate (CR/CRr) as final treatment outcome after completion of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of GVHD Within 1 Year of BMT
Endpoint domain: Adverse events/effects
Primary endpoint: Engraftment at 1 Year Post BMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensory blockade height of spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional state of the patient
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Osteoarthritis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of anesthetic blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-reported Symptoms of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Posttraumatic Stress Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of physical discomfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent change in inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs), Including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) for Participants With Neuroblastoma (Phase I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in life impact of pelvic floor dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in symptoms and quality of life: PFDI-20
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of all-cause device replacements
Endpoint domain: Mortality/survival
Primary endpoint: Battery survival of devices
Endpoint domain: Mortality/survival
Primary endpoint: Cobalt metal ion levels in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in clinical attachment loss (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital survival after 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Mortality at 7, 14 and 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic yield of colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: recommended Phase II dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Itch Numeric Rating Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of regimen-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Rate for hematopoietic engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate for immune reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health Behavior Inventory (HBI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Positive Biomarker Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days free of organ support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on IBS-symptom severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on Hamilton Depression Rating Scale (HAMD-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change on IBS Quality of Life (IBS-QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DC/TMD Symptom Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graded Chronic Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jaw Functional Limitation Scale-20
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of Muscle Cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of people referred from physician and eligible for screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of sessions attended
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants Who Tolerate 40m Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-feasible dose (MFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood nitrate+nitrite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long term favorable outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Sphygmo Readings Within < 5 mmHg, < 10 mmHg, and < 15 mmHg of Gold Standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression free survival time
Endpoint domain: Mortality/survival
Primary endpoint: limb amputation
Endpoint domain: Mortality/survival
Primary endpoint: graft revision
Endpoint domain: Adverse events/effects
Primary endpoint: Cancer rate
Endpoint domain: Mortality/survival
Primary endpoint: Sensations Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive and Negative Affect Schedule
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Brain Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection Improvement of Cancer Outside of the Bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean 24-hour Systolic Blood Pressure Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of intracranial tumor resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improved compliance with Anesthesia Quality Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in SAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total distance travelled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive Function: Full-Scale IQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hand range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Affect on Cardiac Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Damage/Discoloration to Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy: Patient Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy: Patient Recommendation of Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent of drug-drug interaction between erythromycin and midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of drug-drug interaction between diltiazem and midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of drug-drug interaction between diltiazem, erythromycin, and midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Responders Based on Change in Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median Change in Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Resolution of Microscopic Hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mortality (number of all cause death)
Endpoint domain: Mortality/survival
Primary endpoint: Heart failure hospitalization (number of patients hospitalized for heart failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of non-alcoholic fatty liver disease (NAFLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Proportion of subjects maintaining CD4 + cell count above 400 cells/mcL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of clinical end-points (AIDS defining event and death)
Endpoint domain: Mortality/survival
Primary endpoint: Virologic failure with the selection of resistance conferring mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma soluble cluster of differentiation 14 (sCD14)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ease of use of OCT-AFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diameter of passage vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants meeting ASAS20 Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of endemic fungal pathogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 100% healing time of the wound surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient-oriented composite outcome (POCO)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diaphragm muscle myosin content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers for activation of proteolytic pathway in the diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CPCs isolation in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for catheter replacement due to urine retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: plasma Glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Corneal, Ocular, and Internal spherical aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Chair Stands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Falls-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Dual Task Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality at D90
Endpoint domain: Mortality/survival
Primary endpoint: infection recurrence during the ICU stay
Endpoint domain: Adverse events/effects
Primary endpoint: 7 day point prevalence abstinence from cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed All Sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participants' Confidence in Communicating Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline of pituitary tumor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Tumor response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rebound tumor growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes in patients' quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients who return their sputum for p16 methylation analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: K-MMSE score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: K-MoCA score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ADAS-Cog score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: COWAT score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroop score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TMT score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: joint kinetic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in Asthma score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes